GURUFOCUS.COM » STOCK LIST » Financial Services » Insurance » Hubei Biocause Pharmaceutical Co Ltd (SZSE:000627) » Definitions » EV-to-Revenue

Hubei Biocause Pharmaceutical Co (SZSE:000627) EV-to-Revenue : 0.22 (As of Jun. 21, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Hubei Biocause Pharmaceutical Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hubei Biocause Pharmaceutical Co's enterprise value is ¥9,911 Mil. Hubei Biocause Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥45,258 Mil. Therefore, Hubei Biocause Pharmaceutical Co's EV-to-Revenue for today is 0.22.

The historical rank and industry rank for Hubei Biocause Pharmaceutical Co's EV-to-Revenue or its related term are showing as below:

SZSE:000627' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.17   Med: 0.71   Max: 32.38
Current: 0.22

During the past 13 years, the highest EV-to-Revenue of Hubei Biocause Pharmaceutical Co was 32.38. The lowest was 0.17. And the median was 0.71.

SZSE:000627's EV-to-Revenue is ranked better than
86.73% of 490 companies
in the Insurance industry
Industry Median: 1.015 vs SZSE:000627: 0.22

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-21), Hubei Biocause Pharmaceutical Co's stock price is ¥1.85. Hubei Biocause Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥8.89. Therefore, Hubei Biocause Pharmaceutical Co's PS Ratio for today is 0.21.


Hubei Biocause Pharmaceutical Co EV-to-Revenue Historical Data

The historical data trend for Hubei Biocause Pharmaceutical Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Biocause Pharmaceutical Co EV-to-Revenue Chart

Hubei Biocause Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 0.36 0.42 0.57 0.45

Hubei Biocause Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.30 0.49 0.45 0.58

Competitive Comparison of Hubei Biocause Pharmaceutical Co's EV-to-Revenue

For the Insurance - Life subindustry, Hubei Biocause Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hubei Biocause Pharmaceutical Co's EV-to-Revenue Distribution in the Insurance Industry

For the Insurance industry and Financial Services sector, Hubei Biocause Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hubei Biocause Pharmaceutical Co's EV-to-Revenue falls into.



Hubei Biocause Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hubei Biocause Pharmaceutical Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=9910.617/45258.325
=0.22

Hubei Biocause Pharmaceutical Co's current Enterprise Value is ¥9,911 Mil.
Hubei Biocause Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥45,258 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hubei Biocause Pharmaceutical Co  (SZSE:000627) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hubei Biocause Pharmaceutical Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.85/8.885
=0.21

Hubei Biocause Pharmaceutical Co's share price for today is ¥1.85.
Hubei Biocause Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥8.89.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hubei Biocause Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hubei Biocause Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hubei Biocause Pharmaceutical Co (SZSE:000627) Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, Building 1, No. 1 Tianshan Road, Guohua Huijin Center, Zhanghe New District, Hubei Province, Jingmen, CHN, 448000
Hubei Biocause Pharmaceutical Co Ltd is a China-based company engaged in life insurance, health insurance, accident insurance, and other life insurance businesses, medicine, and chemical businesses. The company generates its revenue in the form of premiums.
Executives
Jiang Hai Hua Independent director
Fu Yong Jin Directors, executives
Wu Shi Yan Supervisors

Hubei Biocause Pharmaceutical Co (SZSE:000627) Headlines

No Headlines